全国教育培训机构排名

中英合作 歐普生物科技(集團)有限公司

歐普生物科技有限公司(集團)是專注于大腸桿菌藥系列產品的研發、生產、銷售為一體的獸用藥品制造服務商。公司生產基地坐落于千年古都安陽市歐普工業園,公司總投資5000萬元,占地面積80畝,一期工程建成了粉散劑、預混劑、消毒液GMP標準化生產線。二期工程建成了口服液、中藥提取物等高標準生產線。三期工程飼料添加劑及生物制品等高標準生產線即將開工建設,建成后三條融合全國先進工藝的生產線將進一步完善各品類的產品布局。

 

專注打造大腸桿菌藥是歐普集團13年以來堅持的品牌發展戰略,至2017年,大腸桿菌藥系列產品銷售額占集團總銷售額的60%以上,初步形成了以大腸桿菌藥系列產品為主,以腸道類、綜合保健類為輔的產品構架,歐普集團預計2018年大腸桿菌藥系列產品的銷售額將取得進一步突破。

 
為了進一步提升大腸桿菌藥中國領先品牌的核心競爭力,自2009年起,歐普集團每年投入3%-5%的銷售額用于產品研發,在國外以英國利物浦大學(liverpool.uk)獸醫學院為窗口吸收國際前沿獸醫新技術,在國內初步組建了以河南農大、山東農大、華中農大、河南牧業經濟學院等高等農牧院校教授、研究生為主20余人的研發團隊,正在申報的專利三項,已立項的國家三類新獸藥2個,已基本確立了以中藥及生物制品等防治大腸桿菌病、提高機體免疫力、綠色無殘留的產品為主要研發方向,現已組建在此研發方向上的國家級生物工程企業研發中心。
 
在未來,我們力爭成為中國較具影響力的獸藥研發生產企業。歐普集團將秉承“自強不息、厚德載物”的企業精神,與企業員工以及同行企業互生共贏,全力整合畜牧業資源,適時拓展產業鏈條,增強資本優勢,形成規模效益,必將會更好、更健康的服務于中國畜牧行業,以帶動更多人同赴富裕!
 
China-UK cooperation oup biological technology (Group) Co., Ltd.

OUP Biological Technology Co., Ltd. (Group) is a research and development, the country's first focus on Escherichia coli drug products production, sales as one of the veterinary drug manufacturing service providers. Company production base is located in industrial park of Anyang OUP Millennium ancient capital, the company a total investment of 50000000 yuan, covers an area of 80 mu, the first phase of the project completed powder, premix, disinfection liquid GMP standard production line. The two phase of the project is completed, the oral liquid herbal extracts such as high standard production line. The three phase of the project of feed additive and biological products such as high standard production line is about to start construction, after the completion of the nation's leading three fusion process production line will further improve the various categories of products distribution.

 
Focus to build China's lead brand is Escherichia coli drug OUP group since 8 years adhere to the brand development strategy, to 2012, Escherichia coli drug products accounted for 60% of the group's total sales, the initial formation of the Escherichia coli drug series products, product structure, comprehensive care to intestinal type auxiliary OUP group, is expected in 2015 Escherichia coli drug products sales will exceed 100000000 yuan.
 
In order to further enhance the core competitiveness of Escherichia coli drug China's first brand, since 2009, annual investment OUP group 3%-5% sales for product development, in foreign countries to the University of Liverpool (liverpool.uk) School of veterinary medicine for the window to absorb international advanced veterinary technology at home, the initial formation of the Henan agricultural University, Shandong Agricultural University, Huazhong Agricultural University, Henan Institute of animal husbandry economy of higher agricultural colleges Professor, graduate student 20 person R & D team, was declared the three patents, three class new veterinary drug has been approved to 2 countries, has been basically established the Chinese medicine and biological products such as prevention of colibacillosis, improve immunity, green no residual products as the main direction of research and development, set up a National Biotechnology R & D center on the development direction of the now.
 
In the future, we will strive to become China's most influential veterinary medicine R & D and production enterprises. OUP group will be adhering to the "unremitting self-improvement, social commitment" spirit of enterprise, and enterprise employees and competitors alternate win-win, full integration of animal husbandry resources, to expand the industrial chain, enhance the capital advantage, economies of scale, will be better, more health services in China animal husbandry industry, to bring more people to the rich!
歐普資質: 
全国教育培训机构排名 互联网金融产品有哪些缺点 江西快3 日本av女演儿玉菜菜 模拟炒股和真实炒股有什么区别 日本女优男用 聚宝盆配资 日本av伦理快播电影 贝赢配资 股票配资平台违法了会怎么处理 快乐8 股票融资余额高意味着什么 福彩 好用的股票配资平台 篮彩 警方破获股票配资诈骗 山西泳坛夺金